184 related articles for article (PubMed ID: 14571595)
1. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.
Shekelle P; Morton S; Atkinson S; Suttorp M; Tu W; Heidenreich P; Gubens M; Maglione M; Jungvig L; Roth E; Newberry S
Evid Rep Technol Assess (Summ); 2003 Jul; (82):1-6. PubMed ID: 14571595
[No Abstract] [Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
Thornton PL; Ahmed A
J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
[No Abstract] [Full Text] [Related]
3. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
Shekelle PG; Rich MW; Morton SC; Atkinson CS; Tu W; Maglione M; Rhodes S; Barrett M; Fonarow GC; Greenberg B; Heidenreich PA; Knabel T; Konstam MA; Steimle A; Warner Stevenson L
J Am Coll Cardiol; 2003 May; 41(9):1529-38. PubMed ID: 12742294
[TBL] [Abstract][Full Text] [Related]
4. Role of race in the pharmacotherapy of heart failure.
Kalus JS; Nappi JM
Ann Pharmacother; 2002 Mar; 36(3):471-8. PubMed ID: 11895062
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.
Wong FL; Bhatia S; Landier W; Francisco L; Leisenring W; Hudson MM; Armstrong GT; Mertens A; Stovall M; Robison LL; Lyman GH; Lipshultz SE; Armenian SH
Ann Intern Med; 2014 May; 160(10):672-83. PubMed ID: 24842414
[TBL] [Abstract][Full Text] [Related]
6. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America.
Pharmacotherapy; 2000 May; 20(5):495-522. PubMed ID: 10809338
[No Abstract] [Full Text] [Related]
7. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.
Yeh JM; Nohria A; Diller L
Ann Intern Med; 2014 May; 160(10):661-71. PubMed ID: 24842413
[TBL] [Abstract][Full Text] [Related]
8. Managing patients with heart failure: the reality of clinical practice.
Squire I
Eur Heart J; 2005 Dec; 26(24):2611-3. PubMed ID: 16219652
[No Abstract] [Full Text] [Related]
9. Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment.
Chavey WE; Blaum CS; Bleske BE; Harrison RV; Kesterson S; Nicklas JM;
Am Fam Physician; 2001 Sep; 64(6):1045-54. PubMed ID: 11578026
[TBL] [Abstract][Full Text] [Related]
10. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of heart failure due to systolic dysfunction].
Jiménez-Navarro MF; García-Pinilla JM; Montiel Trujillo A; de Teresa Galván E
Rev Esp Cardiol; 2006 Jul; 6 Suppl F():46-52. PubMed ID: 17144976
[TBL] [Abstract][Full Text] [Related]
13. Beta-blockade in chronic heart failure: does it work in everyone?
Chahoud G; Joseph J
Curr Opin Cardiol; 2003 Sep; 18(5):400-5. PubMed ID: 12960474
[TBL] [Abstract][Full Text] [Related]
14. Slowing the progression of heart failure.
Cohn JN
Eur Heart J; 1996 Nov; 17(11):1609-11. PubMed ID: 8922902
[No Abstract] [Full Text] [Related]
15. [Neurohumoral blocking agents].
Kurisu S; Kihara Y
Nihon Rinsho; 2011 Nov; 69 Suppl 9():394-6. PubMed ID: 22724235
[No Abstract] [Full Text] [Related]
16. Suggestions to improve the quality of life in heart failure.
Thulasimani M; Ramaswamy M
Eur Heart J; 2003 Sep; 24(18):1700. PubMed ID: 14499236
[No Abstract] [Full Text] [Related]
17. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
Porcu M
Ital Heart J; 2002 Jul; 3(7):437-8. PubMed ID: 12189976
[No Abstract] [Full Text] [Related]
18. Importance of in-hospital initiation of evidence-based medical therapies for heart failure: taking advantage of the teachable moment.
Fonorow GC
Congest Heart Fail; 2005; 11(3):153-4. PubMed ID: 15947537
[No Abstract] [Full Text] [Related]
19. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
Weir R; McMurray JJ
Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
[TBL] [Abstract][Full Text] [Related]
20. Heart failure: A case for subspecialized care management.
Smith JJ; Konstam MA
Am Heart J; 1999 Jul; 138(1 Pt 1):14-6. PubMed ID: 10385756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
